ArriVent Biopharma, Inc. Contracts & Agreements
21 Contracts & Agreements
- Business Finance (2 contracts)
- Business Operations (6)
- Human Resources (5)
- Intellectual Property (1)
- Uncategorized (7)
- Amended and Restated Research and Collaboration Agreement, dated August 9, 2024, by and between Aarvik Therapeutics, Inc. and the Registrant (Filed With SEC on November 14, 2024)
- Research and Collaboration Agreement Between Jiangsu Alphamab Biopharmaceuticals Co., Ltd and Arrivent Biopharma, Inc (Filed With SEC on August 14, 2024)
- Description of Securities (Filed With SEC on March 28, 2024)
- Form of Underwriting Agreement (Filed With SEC on January 22, 2024)
- 2024 Employee, Director and Consultant Equity Incentive Plan, form of stock option agreement and form of restricted stock agreement thereunder (Filed With SEC on January 22, 2024)
- ArriVent BioPharma, Inc. Executive Severance Plan (Filed With SEC on January 22, 2024)
- ArriVent BioPharma, Inc. Executive Severance Plan (Filed With SEC on January 5, 2024)
- Non-Employee Director Compensation Policy (Filed With SEC on January 5, 2024)
- ArriVent BioPharma, Inc. Clawback Policy (Filed With SEC on January 5, 2024)
- Offer Letter Agreement, by and between the Registrant and Zhengbin (Bing) Yao, Ph.D., dated May 5, 2021 (Filed With SEC on January 5, 2024)
- Offer Letter Agreement, by and between the Registrant and Stuart Lutzker, M.D., Ph.D., dated May 1, 2021 (Filed With SEC on January 5, 2024)
- Offer Letter Agreement, by and between the Registrant and Robin LaChapelle, dated May 21, 2021 (Filed With SEC on January 5, 2024)
- Offer Letter Agreement, by and between the Registrant and James Kastenmayer, J.D., Ph.D., dated August 11, 2023 (Filed With SEC on January 5, 2024)
- Offer Letter Agreement, by and between the Registrant and Winston Kung, MBA, dated January 3, 2024 (Filed With SEC on January 5, 2024)
- License Agreement, by and between the Registrant and Shanghai Allist Pharmaceuticals Co., Ltd., dated June 29, 2021, as amended by Amendment No. 1, dated November 6, 2023 (Filed With SEC on January 5, 2024)
- Joint Clinical Collaboration Agreement, by and between the Registrant and Shanghai Allist Pharmaceuticals Co., Ltd., dated December 24, 2021 (Filed With SEC on January 5, 2024)
- Research Collaboration Agreement, dated December 21, 2021, by and between Aarvik Therapeutics, Inc. and the Registrant, as amended by Amendment No. 1, effective June 30, 2023 (Filed With SEC on January 5, 2024)
- Clinical Collaboration Agreement, by and between the Registrant and Beijing InnoCare Pharma Tech Co., Ltd., dated June 23, 2023 (Filed With SEC on January 5, 2024)
- Amended and Restated Investors Rights Agreement, dated as of December 16, 2022 (Filed With SEC on January 5, 2024)
- Form of Indemnification Agreement (Filed With SEC on January 5, 2024)
- 2021 Employee, Director and Consultant Equity Incentive Plan, as amended and form of stock option agreement thereunder (Filed With SEC on January 5, 2024)
